Evolus (NASDAQ:EOLS – Get Free Report) and Jushi (OTCMKTS:JUSHF – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
Profitability
This table compares Evolus and Jushi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -14.39% | N/A | -19.03% |
| Jushi | -26.90% | N/A | -16.59% |
Volatility and Risk
Evolus has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Jushi has a beta of -0.71, indicating that its stock price is 171% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
| Jushi | 0 | 0 | 1 | 0 | 3.00 |
Evolus presently has a consensus target price of $16.00, suggesting a potential upside of 138.81%. Given Evolus’ higher probable upside, research analysts clearly believe Evolus is more favorable than Jushi.
Earnings and Valuation
This table compares Evolus and Jushi”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolus | $297.18 million | 1.48 | -$51.64 million | ($0.67) | -10.00 |
| Jushi | $262.91 million | 0.39 | -$68.59 million | ($0.36) | -1.42 |
Evolus has higher revenue and earnings than Jushi. Evolus is trading at a lower price-to-earnings ratio than Jushi, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
90.7% of Evolus shares are held by institutional investors. Comparatively, 21.7% of Jushi shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 23.1% of Jushi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Evolus beats Jushi on 8 of the 13 factors compared between the two stocks.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
About Jushi
Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
